RxSight (RXST)
(Real Time Quote from BATS)
$7.69 USD
+0.04 (0.52%)
Updated Aug 6, 2025 11:04 AM ET
5-Strong Sell of 5 5
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RXST 7.69 +0.04(0.52%)
Will RXST be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RXST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RXST
FMS vs. RXST: Which Stock Is the Better Value Option?
FMS or RXST: Which Is the Better Value Stock Right Now?
RXST: What are Zacks experts saying now?
Zacks Private Portfolio Services
KMDA vs. ACAD: Which Stock Is the Better Value Option?
Do Options Traders Know Something About RxSight Stock We Don't?
RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates
Other News for RXST
RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors | RXST Stock News
RxSight appoints Raymond Cohen to its board of directors
RXST: Morgan Stanley Downgrades RxSight, Price Target Slashed | RXST Stock News
Morgan Stanley Adjusts RxSight (RXST) Outlook Amid Market Challenges | RXST Stock News
RxSight just downgraded at Morgan Stanley, here's why